Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)
| General Information of Drug (ID: DR5328) | ||||||
|---|---|---|---|---|---|---|
| Drug Name |
Loxoprofen gel
|
|||||
| Synonyms |
Loxonin; Loxoprofen; Loxonin Pap; Loxonin Tape; CS-600G; LX-A; LX-P; Loxonin Gel 1%; Lipoxin A, Daiichi Sankyo/Lead Chemical; Lipoxin A, Sankyo/ Lead Chemical; Loxoprofen (gel, pain/ inflammation), Daiichi Sankyo; Loxoprofen (gel, pain/ inflammation), Sankyo; Loxoprofen (patch, pain/inflammation), Daiichi Sankyo/ Lead Chemical; Loxoprofen (patch, pain/inflammation), Sankyo/ Lead Chemical
|
|||||
| Indication | Inflammation [ICD11: 1A00-CA43] | Approved | [1] | |||
| Structure |
![]() |
|||||
| 3D MOL | 2D MOL | |||||
| Pharmaceutical Properties | Molecular Weight | 246.3 | Topological Polar Surface Area | 54.4 | ||
| Heavy Atom Count | 18 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 3 | |||
| Cross-matching ID | ||||||
| The Metabolic Roadmap of This Drug | |||||
|---|---|---|---|---|---|
| The Full List of Drug Metabolites (DM) of This Drug | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
| References | ||||||
|---|---|---|---|---|---|---|
| 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| 2 | Exploring the metabolism of loxoprofen in liver microsomes: the role of cytochrome P450 and UDP-glucuronosyltransferase in its biotransformation. Pharmaceutics. 2018 Aug 2;10(3). pii: E112. | |||||
| 3 | Human dehydrogenase/reductase (SDR family) member 11 is a novel type of 17-hydroxysteroid dehydrogenase | |||||
| 4 | Identification of sulfonyl-loxoprofen as novel phase 2 conjugate in rat | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.


